blood safetydisease surveillancedonor deferral policiespathogen inactivationtransfusion-transmitted infections
Figures from the paper
Abstract (AI)
Since blood is a biologic product, it is unlikely that the risk for transfusion-transmitted infection will ever be reduced to zero. The approach to emerging infections associated with transfusion of blood and blood products includes assessing the transmissibility of the agent by this route; developing effective prevention strategies, including screening tests and donor deferral policies; improving viral and bacterial inactivation procedures; and surveillance for known, as well as emerging and poorly characterized, transfusion-transmitted agents. Vigilance is needed to help ensure proper balance between safety and the availability of blood. Finally, vigilance needs to extend to the developing world, where the basic elements to reduce transfusion-transmitted infections and systems of disease surveillance are often not available.
Key Findings
1
Blood safety requires balancing infection-risk reduction with maintaining adequate blood availability.
2
Developing countries often lack basic measures for preventing transfusion-transmitted infections and systems for disease surveillance, requiring heightened vigilance.
3
Managing emerging transfusion infections requires assessing transmissibility, developing screening and donor-deferral strategies, improving pathogen inactivation, and conducting ongoing surveillance.
4
The risk of transfusion-transmitted infection cannot realistically be reduced to zero because blood is a biologic product.
Research Object
blood and blood products
Research Subject
risk of transfusion-transmitted infections and strategies for maintaining blood safety while preserving availability
Publication Details
Publication Date
1998-09-01
Journal
Publisher
ISSN
Cited by
14
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest